New drug to fight skin cancer gets nod from US drug regulator
HQ Team February 17, 2024: Iovance Biotherapeutics, a San Carlos, California-based company, has been given the nod for its T-cell therapy to treat.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team February 17, 2024: Iovance Biotherapeutics, a San Carlos, California-based company, has been given the nod for its T-cell therapy to treat.
HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies.
HQ Team September 11, 2023: Moderna Inc. announced a pact with Immatics NV, a clinical-stage biopharmaceutical company, to develop cancer therapies using a.
Atara Biotherapeutics gets EC approval for marketing T-cell monothrapy drug Ebvallo
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com